Peter Smith
⬤ Hims & Hers Health shares are hovering around $28.70 as the selling pressure shows no signs of letting up. The stock keeps getting rejected at the 1-day Hull Moving Average, which tells us bears are still in control. Price action has been stuck in a downward channel, repeatedly failing to push past declining resistance levels while staying trapped below key technical barriers.
⬤ Looking at the chart, HIMS has been making lower highs and lower lows since late 2025, painting a pretty clear bearish picture. The $28 level is now the line in the sand - the stock's been testing this zone after sliding down from the mid-$30s. "The structure continues to favor downside follow-through rather than any trend reversal," technical analysts note. We've seen some quick bounces during trading sessions, but none have had enough strength to flip momentum or break above that declining moving average.
⬤ If $28 doesn't hold, the next stop could be $25 - that's the secondary target marked on technical charts. A clean daily close below current support would basically confirm the stock's staying in that descending channel, making a drop to the lower $25 zone more likely. Until HIMS can find its footing and reclaim some of those lost technical levels, we're probably looking at more downside or sideways action instead of any meaningful reversal.
⬤ This matters beyond just one stock because Hims & Hers has become a bellwether in the digital health space. When a high-profile name breaks down at well-defined technical levels, it tends to ripple through sentiment across the sector. How the stock handles this $28 support - and whether it eventually slides to that $25 zone - could shape how traders view risk in similar growth-focused healthcare plays over the coming weeks.
Peter Smith
